Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Остеоартрит в общей практике: лечим боль или болезнь?
Вовк Е.И. Остеоартрит в общей практике: лечим боль или болезнь? Consilium Medicum. 2015; 17 (9): 88–96. DOI: 10.26442/2075-1753_2015.9.88-96
________________________________________________
Vovk E.I. Ostheoarthritis in common practice: pain or disease treatment? Consilium Medicum. 2015; 17 (9): 88–96. DOI: 10.26442/2075-1753_2015.9.88-96
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Увеличение распространенности остеоартрита (ОА) – вызов нашего времени. ОА ведет к ухудшению качества жизни, становится причиной инвалидизации в любом возрасте, приводит к значительным материальным затратам на лечение, в том числе вследствие осложнений терапии нестероидными противовоспалительными препаратами (НПВП), и создает значительную нагрузку для системы здравоохранения. Между тем в научном сообществе и медицинской практике имеет место неопределенность в выборе стратегии терапии пациентов с разными формами ОА и стадиями. Ключами к улучшению медицинской помощи лицам с ОА становятся: 1) выбор режима лечения в соответствии с клиническим фенотипом и коморбидной отягощенностью пациента; 2) раннее назначение фоновой симптом- и структурно-модифицирующей терапии хондроитином и глюкозамином, позволяющей уменьшить потребность в применении НПВП.
Ключевые слова: остеоартрит, болезни старения, коморбидные заболевания, хондроитин, глюкозамин, нестероидные противовоспалительные препараты.
Ключевые слова: остеоартрит, болезни старения, коморбидные заболевания, хондроитин, глюкозамин, нестероидные противовоспалительные препараты.
________________________________________________
The increase of ostheoarthritis (OA) circulation is a modern challenge. OA causes the deterioration of life quality, and is the cause of disabilities in all ages, as it leads to vast material expenses for treatment, especially due to the difficulties imposed by non-steroid antiflammatory drugs (NSAIDs) and creates a significant burden to the healthcare system. In the meantime, an uncertainty in therapy strategy choice when treating the OA patients in different stages of the diseases, takes place in the medical and scientific societies. The keys to improving the medical aid for OA patients are: 1) the optimal regimen choice complacent to the clinical phenotype and comorbid weight of the patient; 2) the early onset appointment of a background symptom- and structure-modificating therapy based on chondroitine and glucosamine, allowing to decrease the need in NSAIDs use.
Key words: ostheoarthritis, aging diseases, comorbid diseases, chondroitine, glucosamine, non-steroid antiflammatory drugs.
Key words: ostheoarthritis, aging diseases, comorbid diseases, chondroitine, glucosamine, non-steroid antiflammatory drugs.
Полный текст
Список литературы
1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(14)62254-6.
2. World Health Statistics 2012. Geneva: World Health Organization. United States Senate Committee on Health, Education, Labor and Pensions, Subcommittee on aging. Centre for Disease Control. Washington, D.C.: Department of Health and Human Services, 2004.
3. Ревматология национальное руководство. Под общ. ред. В.А.Насоновой, Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2010. / Revmatologiia natsional'noe rukovodstvo. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
4. Manton KG et al. Chronic disability trends in elderly United States populations 1982–1994. Proceedings of the National Academy of Sciences 1997; 94: 2593–8.
5. Клинические рекомендации. Ревматология. Под ред. акад. РАМН Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2010. / Klinicheskie rekomendatsii. Revmatologiia. Pod red. akad. RAMN E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
6. Гичев Ю.Ю., Гичев Ю.П. Руководство по микронутриентологии. Роль и значение биологически активных добавок к пище. М.: Триада-Х, 2006; с. 151. / Gichev Iu.Iu., Gichev Iu.P. Rukovodstvo po mikronutrientologii. Rol' i znachenie biologicheski aktivnykh dobavok k pishche. M.: Triada-Х, 2006; s. 151. [in Russian]
7. Glucosamine, ATC code M01AX05. WHO Collaborating Centre for Drug Statistics Methodology.
8. Holmes MW et al. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 1988; 250: 435–41.
9. Prinz RD et al. Biphasic Role of Chondroitin Sulfate in Cardiac Differentiation of Embryonic Stem Cells through Inhibition of Wnt/b-Catenin Signaling. PLoS One 2014; 9 (3): e92381.
10. Duman-Scheel М et al. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417: 299–304.
11. Pulsatelli L et al. New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis 2013; 4 (1): 23–43.
12. Henrotin Y. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis 2010; 2 (6): 335–48.
13. Sofat N et al. Future directions for the management of pain in osteoarthritis. Int J Rheumatol 2014; 9 (2): 197–276.
14. Soni A. Osteoarthritis – aetiology, assessment and management of a heterogeneous condition. 2014; 7 (2): 167–80.
15. Ronca F et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 (Suppl. A): 14–21.
16. Calamia V et al. Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther 2012; 14 (5): R202.
17. Du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001; 70 (1): 5–9.
18. Towheed TE et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
19. Towheed TE. Glucosamine Therapy for Osteoarthritis: An Update. J Rheumatol 2007; 34: 1787–90.
20. Herrero-Beaumont G et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56 (2): 555–67.
21. Reginster JY et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357 (9252): 251–6.
22. Bruyere O et al. Total joint replacement after glucosamine sulphatе treatment in knee ostheoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16 (2): 254–60.
23. Poolsup N et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39 (6): 1080–7.
24. Anderson JW et al. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43 (2): 187–201.
25. Sivojelezova A et al. Glucosamine use in pregnancy: an evaluation of pregnancy outcome. J Womens Health (Larchmt) 2007; 16 (3): 345–8.
26. Volpi N. Chondroitin sulfate for the treatment osteoarthritis? Curr Med Chem 2005; 4: 221–34.
27. Schneider H et al. Symptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized Placebo-Controlled Trials Performed with StructumR. Open Rheumatol J 2012; 6: 183–9.
28. Michel BA et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
29. Wildi LM et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70 (6): 982–9.
30. Hochberg MC et al. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008; 24 (11): 3029–35.
31. Ноchberg M. Structure effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trial of 2-year duration. Osteoarthritis Cartilage 2010; 18: 28–31.
32. Lee YH et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30 (3): 357–63.
33. Lippielo L et al. Beneficial effect of cartilage structure modyifing agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
34. McAlindon TE et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283 (11): 1469–75.
35. Wandel S et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: bmj.c4675.
36. Беневоленская Л.И. и др. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525–8. / Benevolenskaia L.I. i dr. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–8. [in Russian]
37. Лила А.М. и др. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M. i dr. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
38. Алексеева Л.И. и др. Сравнение постоянного и интермиттирующего лечения больных остеоартрозом коленных суставов комбинированным препаратом Терафлекс. Научно-практ. ревматология. 2008; 3: 68–72. / Alekseeva L.I. i dr. Sravnenie postoiannogo i intermittiruiushchego lecheniia bol'nykh osteoartrozom kolennykh sustavov kombinirovannym preparatom Terafleks. Nauchno-prakt. revmatologiia. 2008; 3: 68–72. [in Russian]
39. Clegg DO et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
40. GAIT. Arthritis Rheumatis 2008; 58 (10): 3183–91.
41. Hochberg MC et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2015; 0: 1–8.
42. Fransen М et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. http://ard.bmj.com/on March 6, 2015
43. Martel-Pelletier J et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
44. Jordan KM et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
45. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15 (9): 981–1000.
46. Zhang WL. OARSI recomendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476–99.
47. Hochberg MC et al. As with glucosamine, do not recommend the use of chondroitin sulfate in OA patients. Current ACR treatment guidelines recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74.
48. Кригштейн О.С., Голубев Г.Ш. Оценка доказательств эффективности средств, претендующих называться «структурно-модифицируюими препаратами», 2004–2007 гг. Клин. фармакология и фармакоэкономика. 2008; 1: 55–88. / Krigshtein O.S., Golubev G.Sh. Otsenka dokazatel'stv effektivnosti sredstv, pretenduiushchikh nazyvat'sia «strukturno-modifitsiruiuimi preparatami», 2004–2007 gg. Klin. farmakologiia i farmakoekonomika. 2008; 1: 55–88. [in Russian]
49. Obermeyer W. Economically Motivated Adulteration in the Dietary Supplement Market Place. Consumer Lab.com.
50. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
51. Bannuru RR et al. Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann Intern Med 2015; 162: 46–54.
52. McAlindon TE et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–8.
53. Reginster JY et al. Comments on the discordant recommendations for the use of symptomatic slow acting drugs in knee osteoarthritis. Curr Med Res Opin 2015; 31 (Issue 5).
54. Nelson AE et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014; 43: 701–12.
55. Suri P et al. Epidemiology of osteoarthritis and associated comorbidities. PMR 2012; 4 (5 Suppl.): S10–9.
56. Rosemann T et al. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J Orth Surg Res 2007; 2: 12.
57. Zhu K et al. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007; 32: 2012–8.
58. Hawker GA. All-Cause Mortality and Serious Cardiovascular Events in People with Hip and Knee Osteoarthritis: A Population Based Cohort Study. PLoS One 2014; 9 (3): e91286.
59. Penttinen J. Risk of myocardial infarction among subjects visiting a doctor because of back disorder. A case-control study in Finnish farmers. Spine 1995; 20: 2774–6.
60. Torrance N et al. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010; 14 (4): 380–6.
61. Andersson HI. Increased mortality among individuals with chronic widespread pain relates to lifestyle factors: a prospective population-based study. Disabil Rehabil 2009; 31 (24): 1980–7.
62. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage 2014; 22: 363–88.
63. Grossman E, Messerli FH. Drug-induced Hypertension: An Unappreciated Cause of Hypertension. Am J Med 2012; 125: 14–22.
64. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol 2012; 68: 1533–40.
65. Mc Gettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011. http://journals.plos.org
66. Van Staa TP et al. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27: 563–8.
67. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16 (7): 478–80. / Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 478–80. [in Russian]
2. World Health Statistics 2012. Geneva: World Health Organization. United States Senate Committee on Health, Education, Labor and Pensions, Subcommittee on aging. Centre for Disease Control. Washington, D.C.: Department of Health and Human Services, 2004.
3. Ревматология национальное руководство. Под общ. ред. В.А.Насоновой, Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2010. / Revmatologiia natsional'noe rukovodstvo. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
4. Manton KG et al. Chronic disability trends in elderly United States populations 1982–1994. Proceedings of the National Academy of Sciences 1997; 94: 2593–8.
5. Клинические рекомендации. Ревматология. Под ред. акад. РАМН Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2010. / Klinicheskie rekomendatsii. Revmatologiia. Pod red. akad. RAMN E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
6. Гичев Ю.Ю., Гичев Ю.П. Руководство по микронутриентологии. Роль и значение биологически активных добавок к пище. М.: Триада-Х, 2006; с. 151. / Gichev Iu.Iu., Gichev Iu.P. Rukovodstvo po mikronutrientologii. Rol' i znachenie biologicheski aktivnykh dobavok k pishche. M.: Triada-Х, 2006; s. 151. [in Russian]
7. Glucosamine, ATC code M01AX05. WHO Collaborating Centre for Drug Statistics Methodology.
8. Holmes MW et al. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 1988; 250: 435–41.
9. Prinz RD et al. Biphasic Role of Chondroitin Sulfate in Cardiac Differentiation of Embryonic Stem Cells through Inhibition of Wnt/b-Catenin Signaling. PLoS One 2014; 9 (3): e92381.
10. Duman-Scheel М et al. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417: 299–304.
11. Pulsatelli L et al. New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis 2013; 4 (1): 23–43.
12. Henrotin Y. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis 2010; 2 (6): 335–48.
13. Sofat N et al. Future directions for the management of pain in osteoarthritis. Int J Rheumatol 2014; 9 (2): 197–276.
14. Soni A. Osteoarthritis – aetiology, assessment and management of a heterogeneous condition. 2014; 7 (2): 167–80.
15. Ronca F et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 (Suppl. A): 14–21.
16. Calamia V et al. Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther 2012; 14 (5): R202.
17. Du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001; 70 (1): 5–9.
18. Towheed TE et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
19. Towheed TE. Glucosamine Therapy for Osteoarthritis: An Update. J Rheumatol 2007; 34: 1787–90.
20. Herrero-Beaumont G et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56 (2): 555–67.
21. Reginster JY et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357 (9252): 251–6.
22. Bruyere O et al. Total joint replacement after glucosamine sulphatе treatment in knee ostheoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16 (2): 254–60.
23. Poolsup N et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39 (6): 1080–7.
24. Anderson JW et al. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43 (2): 187–201.
25. Sivojelezova A et al. Glucosamine use in pregnancy: an evaluation of pregnancy outcome. J Womens Health (Larchmt) 2007; 16 (3): 345–8.
26. Volpi N. Chondroitin sulfate for the treatment osteoarthritis? Curr Med Chem 2005; 4: 221–34.
27. Schneider H et al. Symptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized Placebo-Controlled Trials Performed with StructumR. Open Rheumatol J 2012; 6: 183–9.
28. Michel BA et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
29. Wildi LM et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70 (6): 982–9.
30. Hochberg MC et al. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008; 24 (11): 3029–35.
31. Ноchberg M. Structure effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trial of 2-year duration. Osteoarthritis Cartilage 2010; 18: 28–31.
32. Lee YH et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30 (3): 357–63.
33. Lippielo L et al. Beneficial effect of cartilage structure modyifing agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
34. McAlindon TE et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283 (11): 1469–75.
35. Wandel S et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: bmj.c4675.
36. Беневоленская Л.И. и др. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ. 2005; 13 (8): 525–8. / Benevolenskaia L.I. i dr. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–8. [in Russian]
37. Лила А.М. и др. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). РМЖ. 2005; 13 (24): 1618–22. / Lila A.M. i dr. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
38. Алексеева Л.И. и др. Сравнение постоянного и интермиттирующего лечения больных остеоартрозом коленных суставов комбинированным препаратом Терафлекс. Научно-практ. ревматология. 2008; 3: 68–72. / Alekseeva L.I. i dr. Sravnenie postoiannogo i intermittiruiushchego lecheniia bol'nykh osteoartrozom kolennykh sustavov kombinirovannym preparatom Terafleks. Nauchno-prakt. revmatologiia. 2008; 3: 68–72. [in Russian]
39. Clegg DO et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
40. GAIT. Arthritis Rheumatis 2008; 58 (10): 3183–91.
41. Hochberg MC et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2015; 0: 1–8.
42. Fransen М et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. http://ard.bmj.com/on March 6, 2015
43. Martel-Pelletier J et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
44. Jordan KM et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
45. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15 (9): 981–1000.
46. Zhang WL. OARSI recomendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476–99.
47. Hochberg MC et al. As with glucosamine, do not recommend the use of chondroitin sulfate in OA patients. Current ACR treatment guidelines recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74.
48. Кригштейн О.С., Голубев Г.Ш. Оценка доказательств эффективности средств, претендующих называться «структурно-модифицируюими препаратами», 2004–2007 гг. Клин. фармакология и фармакоэкономика. 2008; 1: 55–88. / Krigshtein O.S., Golubev G.Sh. Otsenka dokazatel'stv effektivnosti sredstv, pretenduiushchikh nazyvat'sia «strukturno-modifitsiruiuimi preparatami», 2004–2007 gg. Klin. farmakologiia i farmakoekonomika. 2008; 1: 55–88. [in Russian]
49. Obermeyer W. Economically Motivated Adulteration in the Dietary Supplement Market Place. Consumer Lab.com.
50. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
51. Bannuru RR et al. Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann Intern Med 2015; 162: 46–54.
52. McAlindon TE et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–8.
53. Reginster JY et al. Comments on the discordant recommendations for the use of symptomatic slow acting drugs in knee osteoarthritis. Curr Med Res Opin 2015; 31 (Issue 5).
54. Nelson AE et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014; 43: 701–12.
55. Suri P et al. Epidemiology of osteoarthritis and associated comorbidities. PMR 2012; 4 (5 Suppl.): S10–9.
56. Rosemann T et al. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J Orth Surg Res 2007; 2: 12.
57. Zhu K et al. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007; 32: 2012–8.
58. Hawker GA. All-Cause Mortality and Serious Cardiovascular Events in People with Hip and Knee Osteoarthritis: A Population Based Cohort Study. PLoS One 2014; 9 (3): e91286.
59. Penttinen J. Risk of myocardial infarction among subjects visiting a doctor because of back disorder. A case-control study in Finnish farmers. Spine 1995; 20: 2774–6.
60. Torrance N et al. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010; 14 (4): 380–6.
61. Andersson HI. Increased mortality among individuals with chronic widespread pain relates to lifestyle factors: a prospective population-based study. Disabil Rehabil 2009; 31 (24): 1980–7.
62. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage 2014; 22: 363–88.
63. Grossman E, Messerli FH. Drug-induced Hypertension: An Unappreciated Cause of Hypertension. Am J Med 2012; 125: 14–22.
64. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol 2012; 68: 1533–40.
65. Mc Gettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011. http://journals.plos.org
66. Van Staa TP et al. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27: 563–8.
67. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16 (7): 478–80. / Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 478–80. [in Russian]
________________________________________________
1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(14)62254-6.
2. World Health Statistics 2012. Geneva: World Health Organization. United States Senate Committee on Health, Education, Labor and Pensions, Subcommittee on aging. Centre for Disease Control. Washington, D.C.: Department of Health and Human Services, 2004.
3. Revmatologiia natsional'noe rukovodstvo. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
4. Manton KG et al. Chronic disability trends in elderly United States populations 1982–1994. Proceedings of the National Academy of Sciences 1997; 94: 2593–8.
5. Klinicheskie rekomendatsii. Revmatologiia. Pod red. akad. RAMN E.L.Nasonova. M.: GEOTAR-Media, 2010. [in Russian]
6. Gichev Iu.Iu., Gichev Iu.P. Rukovodstvo po mikronutrientologii. Rol' i znachenie biologicheski aktivnykh dobavok k pishche. M.: Triada-Х, 2006; s. 151. [in Russian]
7. Glucosamine, ATC code M01AX05. WHO Collaborating Centre for Drug Statistics Methodology.
8. Holmes MW et al. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 1988; 250: 435–41.
9. Prinz RD et al. Biphasic Role of Chondroitin Sulfate in Cardiac Differentiation of Embryonic Stem Cells through Inhibition of Wnt/b-Catenin Signaling. PLoS One 2014; 9 (3): e92381.
10. Duman-Scheel М et al. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature 2002; 417: 299–304.
11. Pulsatelli L et al. New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis 2013; 4 (1): 23–43.
12. Henrotin Y. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis 2010; 2 (6): 335–48.
13. Sofat N et al. Future directions for the management of pain in osteoarthritis. Int J Rheumatol 2014; 9 (2): 197–276.
14. Soni A. Osteoarthritis – aetiology, assessment and management of a heterogeneous condition. 2014; 7 (2): 167–80.
15. Ronca F et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998; 6 (Suppl. A): 14–21.
16. Calamia V et al. Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther 2012; 14 (5): R202.
17. Du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther 2001; 70 (1): 5–9.
18. Towheed TE et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005; 2: CD002946.
19. Towheed TE. Glucosamine Therapy for Osteoarthritis: An Update. J Rheumatol 2007; 34: 1787–90.
20. Herrero-Beaumont G et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56 (2): 555–67.
21. Reginster JY et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357 (9252): 251–6.
22. Bruyere O et al. Total joint replacement after glucosamine sulphatе treatment in knee ostheoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthritis Cartilage 2008; 16 (2): 254–60.
23. Poolsup N et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39 (6): 1080–7.
24. Anderson JW et al. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43 (2): 187–201.
25. Sivojelezova A et al. Glucosamine use in pregnancy: an evaluation of pregnancy outcome. J Womens Health (Larchmt) 2007; 16 (3): 345–8.
26. Volpi N. Chondroitin sulfate for the treatment osteoarthritis? Curr Med Chem 2005; 4: 221–34.
27. Schneider H et al. Symptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized Placebo-Controlled Trials Performed with StructumR. Open Rheumatol J 2012; 6: 183–9.
28. Michel BA et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
29. Wildi LM et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70 (6): 982–9.
30. Hochberg MC et al. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008; 24 (11): 3029–35.
31. Ноchberg M. Structure effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trial of 2-year duration. Osteoarthritis Cartilage 2010; 18: 28–31.
32. Lee YH et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30 (3): 357–63.
33. Lippielo L et al. Beneficial effect of cartilage structure modyifing agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999; Suppl. 42: 256.
34. McAlindon TE et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283 (11): 1469–75.
35. Wandel S et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: bmj.c4675.
36. Benevolenskaia L.I. i dr. Effektivnost' preparata Terafleks u bol'nykh s osteoartrozom kolennykh i tazobedrennykh sustavov (otkrytoe randomizirovannoe issledovanie). RMZh. 2005; 13 (8): 525–8. [in Russian]
37. Lila A.M. i dr. Terafleks v kompleksnoi terapii osteoartroza kolennykh sustavov i osteokhondroza pozvonochnika (rezul'taty klinicheskogo issledovaniia). RMZh. 2005; 13 (24): 1618–22. [in Russian]
38. Alekseeva L.I. i dr. Sravnenie postoiannogo i intermittiruiushchego lecheniia bol'nykh osteoartrozom kolennykh sustavov kombinirovannym preparatom Terafleks. Nauchno-prakt. revmatologiia. 2008; 3: 68–72. [in Russian]
39. Clegg DO et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354 (8): 795–808.
40. GAIT. Arthritis Rheumatis 2008; 58 (10): 3183–91.
41. Hochberg MC et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2015; 0: 1–8.
42. Fransen М et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. http://ard.bmj.com/on March 6, 2015
43. Martel-Pelletier J et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015; 74: 547–56.
44. Jordan KM et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
45. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15 (9): 981–1000.
46. Zhang WL. OARSI recomendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476–99.
47. Hochberg MC et al. As with glucosamine, do not recommend the use of chondroitin sulfate in OA patients. Current ACR treatment guidelines recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64: 465–74.
48. Krigshtein O.S., Golubev G.Sh. Otsenka dokazatel'stv effektivnosti sredstv, pretenduiushchikh nazyvat'sia «strukturno-modifitsiruiuimi preparatami», 2004–2007 gg. Klin. farmakologiia i farmakoekonomika. 2008; 1: 55–88. [in Russian]
49. Obermeyer W. Economically Motivated Adulteration in the Dietary Supplement Market Place. Consumer Lab.com.
50. Zhang WL et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
51. Bannuru RR et al. Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann Intern Med 2015; 162: 46–54.
52. McAlindon TE et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–8.
53. Reginster JY et al. Comments on the discordant recommendations for the use of symptomatic slow acting drugs in knee osteoarthritis. Curr Med Res Opin 2015; 31 (Issue 5).
54. Nelson AE et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The Chronic Osteoarthritis Management Initiative of the U.S. Bone and Joint Initiative. Semin Arthritis Rheum 2014; 43: 701–12.
55. Suri P et al. Epidemiology of osteoarthritis and associated comorbidities. PMR 2012; 4 (5 Suppl.): S10–9.
56. Rosemann T et al. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J Orth Surg Res 2007; 2: 12.
57. Zhu K et al. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007; 32: 2012–8.
58. Hawker GA. All-Cause Mortality and Serious Cardiovascular Events in People with Hip and Knee Osteoarthritis: A Population Based Cohort Study. PLoS One 2014; 9 (3): e91286.
59. Penttinen J. Risk of myocardial infarction among subjects visiting a doctor because of back disorder. A case-control study in Finnish farmers. Spine 1995; 20: 2774–6.
60. Torrance N et al. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010; 14 (4): 380–6.
61. Andersson HI. Increased mortality among individuals with chronic widespread pain relates to lifestyle factors: a prospective population-based study. Disabil Rehabil 2009; 31 (24): 1980–7.
62. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage 2014; 22: 363–88.
63. Grossman E, Messerli FH. Drug-induced Hypertension: An Unappreciated Cause of Hypertension. Am J Med 2012; 125: 14–22.
64. Fournier JP et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol 2012; 68: 1533–40.
65. Mc Gettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011. http://journals.plos.org
66. Van Staa TP et al. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 2000; 27: 563–8.
67. Vertkin A.L., Alekseeva L.I., Naumov A.V. i dr. Osteoartroz v praktike vracha-terapevta. RMZh. 2008; 16 (7): 478–80. [in Russian]
Авторы
Е.И.Вовк
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
shurick046@yandex.ru
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
shurick046@yandex.ru
________________________________________________
E.I.Vovk
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul.Delegatskaia, d. 20, str. 1
shurick046@yandex.ru
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul.Delegatskaia, d. 20, str. 1
shurick046@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.